A therapeutic animal study showed that MCC950, an NLRP3 selective inhibitor, improves NAFLD pathology and fibrosis in obese diabetic mice and reduces liver fibrosis in MCD-fed mice [147]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.